Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients - Test2 - elhamkhani - TriplyDB

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

http://www.wikidata.org/entity/Q28390399

about

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity Current issues in malignant pleural mesothelioma evaluation and management Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Antibody-based immunotherapy for malignant glioma.Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms.KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients Old medications and new targeted therapies in systemic sclerosis.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity Immune therapies for malignant mesothelioma.Overcoming tumor-mediated immunosuppression.Searching for targets for the systemic therapy of mesothelioma.Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.Autophagy: controlling cell fate in rheumatic diseases.The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis.Transforming growth factor-β: A therapeutic target for cancer.Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions.Targeted Therapies Against Growth Factor Signaling in Breast Cancer.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.Immunotherapy advances for mesothelioma treatment.

P2860

Q26797238-915A2D5D-34CB-44AA-A611-123D608D3F0C Q28075996-5EDA4483-EA2E-4C92-BE68-D5E4FFD39ED9 Q28393560-9B11BB35-0BAD-4CE9-9A50-A6457DD086E0 Q28395597-2F9D8A89-F40F-4658-9FD8-0FE44FA1D068 Q34120472-FAF2935E-4FE4-47C2-BBB2-5EDE6F63BDAC Q35840270-0E694D77-8BE5-4806-8B97-4B0CA2CC4726 Q36035319-4627AECA-390E-4A3B-AFCC-DCC9A07207AC Q36040200-BA7E6C73-C6A1-4952-91A2-D11B762EB778 Q36154430-A00A45F3-4DFC-4FD8-9FF3-D2E83AEE5C6B Q38203261-9EA58381-91E5-4241-A637-40B68210FD73 Q38212149-2CCE9E28-D8AF-4DEE-A01A-66E4268F6A04 Q38262255-C611C43B-142A-431A-B105-B70F7D54E644 Q38365768-480A0DA2-9F3A-4525-B75B-65EBAD4F39E8 Q38416306-0D6005D6-1D8F-4CB6-867E-5AAFEC2F64A7 Q38873681-BA4613BB-CDEC-4687-A715-07ABD4B0E1C0 Q39290714-FA90B8C3-EEFB-43A3-BCC0-AC1B3AFC322D Q39346505-D2B156A7-9ABB-4DCA-8BAC-1B618A44B0B5 Q39415827-1D0E276B-E749-4AFE-80DE-6320A1332360 Q39595554-296DCEF9-C576-4B93-9076-5F00F2BD44F9 Q42551215-0EEB61B0-9E5F-4110-A9DA-382810FA24DD Q47559665-0800053F-6520-4E46-9D32-F3AF703993CA Q50041876-6ED179AF-9DB4-4BF5-AE49-C83A3FB7C4A9 Q51823843-19961777-ED5C-459C-99FD-A1C5A7414635

P2860

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

http://www.wikidata.org/entity/Q28390399

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Immunological effects of the T ...... pleural mesothelioma patients

@ast

Immunological effects of the T ...... pleural mesothelioma patients

@en

Immunological effects of the T ...... pleural mesothelioma patients

@nl

type

label

Immunological effects of the T ...... pleural mesothelioma patients

@ast

Immunological effects of the T ...... pleural mesothelioma patients

@en

Immunological effects of the T ...... pleural mesothelioma patients

@nl

prefLabel

Immunological effects of the T ...... pleural mesothelioma patients

@ast

Immunological effects of the T ...... pleural mesothelioma patients

@en

Immunological effects of the T ...... pleural mesothelioma patients

@nl

P1433

Q28390399-48F3EB84-A75F-4A32-9132-45C0E4B03513

P1476

Q28390399-0B480C62-6433-4C9E-83CA-DC730A0613B1

P2093

Q28390399-0AD02F3A-A29B-44A1-B1D1-8FE778EC4605

Q28390399-158A5026-B735-4453-9E28-95770A458EBB

Q28390399-3BBCBB55-4268-4302-B936-659E6FDCDE7A

Q28390399-43C60562-83EC-4690-A97D-4E88BA1FEFEA

Q28390399-4CA149C4-9358-4D58-819C-C76C472B716B

Q28390399-712CEFCB-642F-4934-AA10-A9B7D8737F30

Q28390399-7DDA8CAA-5F90-4658-B811-EB8C71A290A1

Q28390399-8761D635-C323-40C9-8AFB-7D4E83B5E5F0

Q28390399-A9911032-B05B-4303-8C48-D4C2CDE809F4

Q28390399-B226D448-BC4C-4CC0-955B-A941394CA5EA

P2860

Q28390399-094399E3-244E-4BE0-964A-B50485208F51

Q28390399-0FC7E0F5-2E4F-43C4-9130-56B74813B9A8

Q28390399-14FF0B3C-B376-476E-9F85-7CA2CE5B41AA

Q28390399-1621C98B-9E91-4208-A605-F1079A07A4C3

Q28390399-1EA73574-5A31-4F15-A16E-582207A3A98D

Q28390399-1F8C42B9-0163-45B4-B0A2-AF7D1F2A9332

Q28390399-244C6761-A539-4DF2-AAA6-78AEB663F226

Q28390399-26A1C3EB-D991-43C2-80E2-5499BBB48D23

Q28390399-2B2D2177-86D9-4127-9AF8-DFA83936425B

Q28390399-2D20595C-E35D-42E7-BB93-D79C149076AC

P304

Q28390399-B986D014-333F-42AE-8BAD-344DE8526439

P31

Q28390399-C3952B82-F7A2-4C7F-813C-44CFED1B98A1

P3181

Q28390399-90EBC9EB-0DEF-48F0-8A20-64E1017719A3

P356

Q28390399-82ACFBE5-F645-42EB-9AAE-E5DC9F3CED7E

P407

Q28390399-687C03A6-7E5A-412A-AE63-20172DFF5345

P433

Q28390399-028BD0D8-FBA6-4B44-ADC8-AF9B1A631531

P478

Q28390399-495BAC85-9626-44EB-9DBA-C10C7A9BCA3A

P577

Q28390399-BC8BA568-5A47-45F5-A105-18300683B05F

P5875

Q28390399-A8DDE61C-5E30-4C6F-908B-567DAEC02573

P698

Q28390399-B76B0303-DD1B-4ECD-9901-C246FC0252D8

P921

Q28390399-F3E5DCCF-FF49-40DB-A5DC-2EA88AA3FB3B

P932

Q28390399-F7618D23-FCAB-464D-B18A-074608D63E37

P3181

P356

P1433

P1476

Immunological effects of the T ...... pleural mesothelioma patients

@en

P2093

Anjana Ranganathan

http://www.w3.org/2001/XMLSchema#string

Corey J Langer

http://www.w3.org/2001/XMLSchema#string

Daniel F Heitjan

http://www.w3.org/2001/XMLSchema#string

Daniel Schwed

http://www.w3.org/2001/XMLSchema#string

Emmanouil Papasavvas

http://www.w3.org/2001/XMLSchema#string

Hedy L Kindler

http://www.w3.org/2001/XMLSchema#string

James P Stevenson

http://www.w3.org/2001/XMLSchema#string

Jennifer Hull

http://www.w3.org/2001/XMLSchema#string

Jing Sun

http://www.w3.org/2001/XMLSchema#string

John M McPherson

http://www.w3.org/2001/XMLSchema#string

P2860

Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells

Complexities of TGF-β targeted cancer therapy.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

TGFbeta in Cancer

TGF-beta: a master of all T cell trades

TGF-beta signaling in tumor suppression and cancer progression

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.

Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.

P304

e26218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1153618

http://www.w3.org/2001/XMLSchema#string

P356

10.4161/ONCI.26218

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258216393

http://www.w3.org/2001/XMLSchema#string

P698

24179709

http://www.w3.org/2001/XMLSchema#string

P921

P932

3812201

http://www.w3.org/2001/XMLSchema#string